TL;DR
This study reveals that PANDER, a protein previously linked to metabolic disorders, acts as a nuclear co-activator for the transcription factor FOXO1 in liver cells. By directly interacting with FOXO1, PANDER enhances its ability to promote glucose production, offering a new mechanistic insight into how metabolic dysregulation occurs in conditions like obesity and diabetes.
What Problem Does This Paper Address?
Metabolic syndrome and type 2 diabetes are characterized by dysregulated glucose metabolism, particularly in the liver, where excessive glucose production (gluconeogenesis) contributes to hyperglycemia. The transcription factor FOXO1 is a known key regulator of gluconeogenesis, but the precise mechanisms that control its activity, especially in the context of obesity and insulin resistance, are not fully understood. While PANDER (also known as FAM3B) has been implicated in promoting gluconeogenesis and lipogenesis, its specific molecular role and mechanism of action in hepatocytes remained unclear. This paper aims to elucidate how PANDER influences gluconeogenesis by investigating its interaction with FOXO1.
Methods
The researchers employed a multi-pronged approach to investigate PANDER's role:
- Immunohistochemistry and Confocal Microscopy: Used to visualize the cellular and subcellular localization of PANDER and FOXO1 in mouse livers and cultured human (HepG2) and mouse hepatocytes.
- Cell Fractionation: Mitochondria, cytosolic, and nuclear fractions were isolated to confirm PANDER's presence in the nucleus.
- Co-Immunoprecipitation (Co-IP): Performed to demonstrate direct physical interaction between PANDER and FOXO1 in both liver tissues and cell cultures.
- Adenovirus-mediated Gene Expression: Used to overexpress PANDER and FOXO1 in hepatocytes to study their functional effects.
- siRNA-mediated Gene Silencing: Employed to knock down PANDER and FOXO1 to assess their necessity for PANDER-induced effects.
- Luciferase Reporter Assays: Utilized to measure the transcriptional activity of FOXO1 on gluconeogenic gene promoters (specifically G6Pase).
- Glucose Production Assays: Quantified the amount of glucose produced by hepatocytes under various experimental conditions.
- Western Blotting: Used to assess protein levels of PANDER, FOXO1, phosphorylated FOXO1, and key gluconeogenic enzymes (PEPCK and G6Pase).
- FOXO1 Inhibitor Studies: Employed the specific FOXO1 inhibitor AS1842856 to evaluate the impact of PANDER on FOXO1's inhibitory response.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- PANDER is a Nuclear Player: Contrary to expectations of a secreted factor, PANDER is found to be abundantly present in the nucleus of hepatocytes, suggesting an intracellular mechanism of action.
- PANDER and FOXO1 are Partners in the Nucleus: PANDER directly interacts with FOXO1 within the nucleus, forming a complex that is crucial for regulating gluconeogenesis.
- PANDER Enhances FOXO1's Gluconeogenic Drive: PANDER doesn't just interact with FOXO1; it actively enhances FOXO1's ability to promote the expression of genes involved in glucose production.
- Insulin Resistance Link: PANDER's interaction with FOXO1 appears to interfere with insulin's normal signaling pathway, specifically by preventing FOXO1's translocation out of the nucleus upon insulin stimulation, a hallmark of insulin resistance.
- Therapeutic Target Potential: The findings suggest that targeting the PANDER-FOXO1 interaction could be a novel strategy for treating metabolic disorders like type 2 diabetes and fatty liver disease.
Key Results
- PANDER protein is localized in both the cytoplasm and nucleus of mouse and human hepatocytes, with a significant portion found in the nucleus (50-60% in mouse, 70% in human).
- Nuclear PANDER distribution is increased in the livers of obese diabetic mice (db/db) and mice fed a high-fat diet (HFD).
- PANDER directly interacts with FOXO1 in the nucleus of both mouse and human hepatocytes. This interaction is enhanced by PANDER overexpression and is more pronounced in obese mouse livers.
- PANDER overexpression leads to increased expression of gluconeogenic genes (PEPCK and G6Pase) at both mRNA and protein levels.
- PANDER overexpression promotes glucose production in HepG2 cells and primary mouse hepatocytes.
- PANDER augments FOXO1's transcriptional activity on the G6Pase promoter.
- PANDER overexpression impairs the inhibitory effects of the FOXO1 inhibitor AS1842856 on gluconeogenic gene expression and glucose production.
- Silencing of FOXO1 inhibits PANDER-promoted gluconeogenesis, while silencing of PANDER has a lesser effect on FOXO1-induced gluconeogenesis.
- PANDER overexpression prevents the insulin-induced nuclear exclusion of FOXO1 in hepatocytes.
Limitations and Future Work
- PANDER's Nuclear Translocation Mechanism: The paper notes that PANDER has a signal peptide but not a typical nuclear localization peptide, and the mechanism by which it translocates to the nucleus remains unclear. Future work could investigate this process, potentially through interaction with FOXO1 itself.
- PANDER Secretion Beyond Pancreatic Islets: While PANDER is known to be secreted from pancreatic islets, its secretion from hepatocytes is not definitively established in this study. The paper raises the question of whether hepatocytes secrete PANDER or if increased hepatic PANDER expression triggers a feedback loop with pancreatic islets.
- Mapping the Interaction Domain: The specific region of PANDER that interacts with FOXO1 is not identified. Future research could focus on mapping this binding domain to develop more targeted therapeutic interventions.
- Other FOXO Family Members: The study primarily focuses on FOXO1. While PANDER might also interact with other FOXO family members (e.g., FOXO3, FOXO6), this was not extensively explored.
- Therapeutic Development: The authors suggest that targeting the PANDER-FOXO1 interaction holds promise for treating type 2 diabetes and fatty liver disease, implying that developing inhibitors or modulators of this interaction would be a logical next step.
Summary updated